These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34718044)

  • 41. [Atypical serological profiles in hepatitis B infections: investigation of S gene mutations in cases with concurrently positive for HBsAg and anti-HBs].
    Aydın N; Kırdar S; Uzun N; Eyigör M; Sayan M
    Mikrobiyol Bul; 2016 Oct; 50(4):535-543. PubMed ID: 28124958
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The hepatitis B vaccine protects re-exposed health care workers, but does not provide sterilizing immunity.
    Werner JM; Abdalla A; Gara N; Ghany MG; Rehermann B
    Gastroenterology; 2013 Nov; 145(5):1026-34. PubMed ID: 23916846
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Toll-like receptor 7 agonist, GS-986, is an immune-stimulant inducing follicular helper T cells and expanding HBs antigen-specific B cells in vitro.
    Mori T; Yoshio S; Yoshikawa S; Tsustui Y; Sakata T; Yoshida Y; Sakamoto Y; Kawai H; Osawa Y; Yamazoe T; Aoki Y; Fletcher SP; Kanto T
    Liver Int; 2023 Jun; 43(6):1213-1224. PubMed ID: 37029645
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PASylated interferon α efficiently suppresses hepatitis B virus and induces anti-HBs seroconversion in HBV-transgenic mice.
    Xia Y; Schlapschy M; Morath V; Roeder N; Vogt EI; Stadler D; Cheng X; Dittmer U; Sutter K; Heikenwalder M; Skerra A; Protzer U
    Antiviral Res; 2019 Jan; 161():134-143. PubMed ID: 30439382
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice.
    Dai S; Zhuo M; Song L; Chen X; Yu Y; Zang G; Tang Z
    Immunobiology; 2016 Jul; 221(7):813-21. PubMed ID: 26874581
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of antiviral - passive - active immunization ("sandwich") therapeutic strategy for functional cure of chronic hepatitis B in mice.
    Shi B; Wu Y; Wang C; Li X; Yu F; Wang B; Yang Z; Li J; Liang M; Wen Y; Ying T; Yuan Z
    EBioMedicine; 2019 Nov; 49():247-257. PubMed ID: 31680000
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Review article: clinical pharmacology of current and investigational hepatitis B virus therapies.
    Smolders EJ; Burger DM; Feld JJ; Kiser JJ
    Aliment Pharmacol Ther; 2020 Jan; 51(2):231-243. PubMed ID: 31840863
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-hepatitis B virus activity of wogonin in vitro and in vivo.
    Guo Q; Zhao L; You Q; Yang Y; Gu H; Song G; Lu N; Xin J
    Antiviral Res; 2007 Apr; 74(1):16-24. PubMed ID: 17280723
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study.
    Wong RJ; Nguyen MT; Trinh HN; Chan C; Huynh A; Ly MT; Nguyen HA; Nguyen KK; Torres S; Yang J; Liu B; Garcia RT; Bhuket T; Baden R; Levitt B; da Silveira E; Gish RG
    J Viral Hepat; 2017 Dec; 24(12):1089-1097. PubMed ID: 28581644
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of the HCV core protein on the immune response to HBV surface antigen and on HBV gene expression and replication in vivo.
    Zhu W; Wu C; Deng W; Pei R; Wang Y; Cao L; Qin B; Lu M; Chen X
    PLoS One; 2012; 7(9):e45146. PubMed ID: 23024803
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti-viral therapy with an interferon-free regimen.
    Londoño MC; Lens S; Mariño Z; Bonacci M; Ariza X; Broquetas T; Pla A; Bartres C; Adriani MV; Rodríguez-Tajes S; Costa J; Carrión JA; Pérez-Del-Pulgar S; Forns X
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1156-1161. PubMed ID: 28206681
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir.
    de Niet A; Jansen L; Zaaijer HL; Klause U; Takkenberg B; Janssen HL; Chu T; Petric R; Reesink HW
    Antivir Ther; 2014; 19(3):259-67. PubMed ID: 24256626
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Successful interferon treatment in a patient chronically infected with hepatitis B virus carrying unusual S- (and P-) mutants in the presence of anti-HBs antibodies.
    Frider B; Alessio A; Pozzati M; Cuestas ML; Mathet VL; Oubiña JR
    Liver Int; 2007 Jun; 27(5):727-30. PubMed ID: 17498261
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.
    Boni C; Janssen HLA; Rossi M; Yoon SK; Vecchi A; Barili V; Yoshida EM; Trinh H; Rodell TC; Laccabue D; Alfieri A; Brillo F; Fisicaro P; Acerbi G; Pedrazzi G; Andreone P; Cursaro C; Margotti M; Santoro R; Piazzolla V; Brunetto MR; Coco B; Cavallone D; Zhao Y; Joshi A; Woo J; Lau AH; Gaggar A; Subramanian GM; Massetto B; Fung S; Ahn SH; Ma X; Mangia A; Ferrari C
    Gastroenterology; 2019 Jul; 157(1):227-241.e7. PubMed ID: 30930022
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-hepatitis B virus (HBV) response of imiquimod based toll like receptor 7 ligand in hbv-positive human hepatocelluar carcinoma cell line.
    Das D; Sengupta I; Sarkar N; Pal A; Saha D; Bandopadhyay M; Das C; Narayan J; Singh SP; Chakrabarti S; Chakravarty R
    BMC Infect Dis; 2017 Jan; 17(1):76. PubMed ID: 28088184
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
    Harigai M; Winthrop K; Takeuchi T; Hsieh TY; Chen YM; Smolen JS; Burmester G; Walls C; Wu WS; Dickson C; Liao R; Genovese MC
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibody-mediated immunotherapy against chronic hepatitis B virus infection.
    Gao Y; Zhang TY; Yuan Q; Xia NS
    Hum Vaccin Immunother; 2017 Aug; 13(8):1768-1773. PubMed ID: 28521640
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hepatitis B virus infection after renal transplantation in the presence of antibody to hepatitis B surface antigen immunity.
    Kim KH; Ahn SH; Chung HY; Paik YH; Lee KS; Kim YS; Chon CY; Moon YM; Han KH
    J Gastroenterol Hepatol; 2004 Aug; 19(8):847-53. PubMed ID: 15242485
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance.
    Sacherl J; Kosinska AD; Kemter K; Kächele M; Laumen SC; Kerth HA; Öz EA; Wolff LS; Su J; Essbauer S; Sutter G; Scholz M; Singethan K; Altrichter J; Protzer U
    JHEP Rep; 2023 Feb; 5(2):100603. PubMed ID: 36714793
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection.
    Su WJ; Ho MC; Ni YH; Chen HL; Hu RH; Wu YM; Chang MH; Lee PH
    J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):203-8. PubMed ID: 19179883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.